Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment

This study is testing Auger Molecular Therapy (AMT) — a type of targeted radiation therapy — for patients with malignant skin lesions (cutaneous metastases) from various types of advanced cancers including head and neck, breast, gastrointestinal, pancreatic, liver, endometrial, and prostate cancers. These skin lesions are often painful and difficult to treat. AMT uses a radioactive compound that targets cancer cells directly, delivering radiation from very short distances to minimize harm to surrounding healthy tissue. Participants receive the therapy applied to their skin lesions in outpatient sessions. The study measures how well the lesions respond and monitors for side effects. You may be eligible if: - You are 18 years or older - You have histologically confirmed advanced cancer (head/neck, breast, GI, pancreatic, liver, endometrial, or prostate cancer) - You have malignant skin lesions from metastasis or tumor invasion that fit within the treatment applicator (6 cm diameter) - The lesion is 0.7 cm or less in thickness - Your ECOG performance status is 3 or less You may NOT be eligible if: - You have a connective tissue disease or known radiation sensitivity syndrome - The lesion is on the eyelid, eye, genitalia, lip, or near the carotid artery - You are HIV positive - You are pregnant or breastfeeding - You are taking therapeutic anticoagulants Talk to your doctor to see if this trial is right for you.